Search
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions
Categories: Compounds used in a research, industrial, or household settingStannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines
Casirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigational[A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.
Varicella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalThe main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). … Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in
Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein ENonivamide
go.drugbank.com/drugs/DB11324ApprovedNonivamide is found in herbs and spices. It is an alkaloid from the Capsicum species. … This drug has been studied in combination with Nicarboxil in the treatment of lower back pain [L2642].
Synonyms: N-Vanillylnonamide, N-Nonanoyl vanillylamideNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalFood and Drug Administration on August 1, 2017. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitNormethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.
Rivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24H